AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα levels.

Trial Details

NCT ID
NCT07218809
Phase
PHASE3
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • AZD5335
  • Mirvetuximab Soravtansine (MIRV)
  • Paclitaxel
  • Pegylated liposomal Doxorubicin (PLD)
  • Topotecan
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Little Rock, Arkansas, United States|34.74648,-92.28959
  • La Jolla, California, United States|32.84727,-117.2742
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Fort Lauderdale, Florida, United States|26.12231,-80.14338

Key Eligibility Criteria

  • Participants with confirmed diagnosis of high-grade serous EOC, primary peritoneal cancer, or fallopian tube cancer.
  • Participants must have platinum-resistant disease:
  • Participants who have only had one prior line of platinum-based therapy must have received at least 4 cycles of platinum, must have had a response …
  • Participants who have received 2 or 3 lines of platinum therapy must have progressed ≤ 6 months after the date of the last dose of platinum.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →